1. Home
  2. AGEN vs PDEX Comparison

AGEN vs PDEX Comparison

Compare AGEN & PDEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Agenus Inc.

AGEN

Agenus Inc.

HOLD

Current Price

$3.05

Market Cap

126.2M

Sector

Health Care

ML Signal

HOLD

Logo Pro-Dex Inc.

PDEX

Pro-Dex Inc.

HOLD

Current Price

$39.91

Market Cap

106.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AGEN
PDEX
Founded
1994
1978
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
126.2M
106.5M
IPO Year
2000
N/A

Fundamental Metrics

Financial Performance
Metric
AGEN
PDEX
Price
$3.05
$39.91
Analyst Decision
Buy
Strong Buy
Analyst Count
2
1
Target Price
$14.50
$56.00
AVG Volume (30 Days)
613.6K
25.5K
Earning Date
03-10-2026
01-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
76.21
EPS
N/A
3.41
Revenue
$106,829,000.00
$72,101,000.00
Revenue This Year
$5.19
$7.22
Revenue Next Year
$68.25
N/A
P/E Ratio
N/A
$11.59
Revenue Growth
N/A
18.19
52 Week Low
$1.38
$23.47
52 Week High
$7.34
$70.26

Technical Indicators

Market Signals
Indicator
AGEN
PDEX
Relative Strength Index (RSI) 45.17 50.61
Support Level $2.76 $37.07
Resistance Level $3.15 $40.50
Average True Range (ATR) 0.18 1.74
MACD 0.02 -0.06
Stochastic Oscillator 61.00 53.97

Price Performance

Historical Comparison
AGEN
PDEX

About AGEN Agenus Inc.

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

About PDEX Pro-Dex Inc.

Pro-Dex Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers (OEMs) to various countries. Its product portfolio includes autoclavable, battery-powered, electric, and multi-function surgical drivers and shavers used mainly in orthopedic, thoracic, and craniomaxillofacial markets. The company also provides engineering, quality, regulatory consulting services, and manufactures rotary air motors utilized in various industries. Operating out of ISO-certified facilities in California, Pro-Dex serves hospitals, medical labs, and high-tech manufacturers, generating revenue through sales of surgical instruments and related services.

Share on Social Networks: